Coordinated improvement in glucose tolerance, liver steatosis and obesity-associated inflammation by cannabinoid 1 receptor antagonism in fat Aussie mice
- 8 March 2011
- journal article
- Published by Springer Nature in International Journal of Obesity
- Vol. 35 (12) , 1539-1548
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- CB1 Antagonism Exerts Specific Molecular Effects on Visceral and Subcutaneous Fat and Reverses Liver Steatosis in Diet-Induced Obese MiceDiabetes, 2010
- Hepatic CB1 receptor is required for development of diet-induced steatosis, dyslipidemia, and insulin and leptin resistance in miceJournal of Clinical Investigation, 2008
- The Endocannabinoid System and the Control of Glucose HomeostasisJournal of Neuroendocrinology, 2008
- Abdominal obesity and metabolic syndromeNature, 2006
- Mechanisms linking obesity to insulin resistance and type 2 diabetesNature, 2006
- Dysregulation of the Peripheral and Adipose Tissue Endocannabinoid System in Human Abdominal ObesityDiabetes, 2006
- Adaptive failure to high-fat diet characterizes steatohepatitis in Alms1 mutant miceBiochemical and Biophysical Research Communications, 2006
- How many sites of action for endocannabinoids to control energy metabolism?International Journal of Obesity, 2006
- The Cannabinoid CB1 Receptor Antagonist Rimonabant (SR141716) Inhibits Cell Proliferation and Increases Markers of Adipocyte Maturation in Cultured Mouse 3T3 F442A PreadipocytesMolecular Pharmacology, 2006
- Diet-induced muscle insulin resistance in rats is ameliorated by acute dietary lipid withdrawal or a single bout of exercise: parallel relationship between insulin stimulation of glucose uptake and suppression of long-chain fatty acyl-CoADiabetes, 1997